Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature için istatistikler

Toplam ziyaret

views
Fifty-five months progression-free survival with crizotinib treatment in coexistence of ALK and ROS1 rearrangements in lung adenocarcinoma: an extremely rare case and review of the literature 0

Aylık toplam ziyaret

views
Mayıs 2024 0
Haziran 2024 0
Temmuz 2024 0
Ağustos 2024 0
Eylül 2024 0
Ekim 2024 0
Kasım 2024 0